{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T17:36:45Z","timestamp":1777225005070,"version":"3.51.4"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100006722","name":"Centrum f\u00d6r Klinisk Forskning Dalarna","doi-asserted-by":"publisher","award":["CKFUU\u2010988756"],"award-info":[{"award-number":["CKFUU\u2010988756"]}],"id":[{"id":"10.13039\/501100006722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006722","name":"Centrum f\u00d6r Klinisk Forskning Dalarna","doi-asserted-by":"publisher","award":["CKFUU\u20101003113"],"award-info":[{"award-number":["CKFUU\u20101003113"]}],"id":[{"id":"10.13039\/501100006722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014688","name":"Region Uppsala","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>High\u2010dose melphalan (HDM) followed by autologous haematopoietic stem cell transplantation (ASCT) remains the standard of care for eligible patients with multiple myeloma (MM). Our objective was to evaluate the effectiveness and safety of adding bortezomib and bendamustine to melphalan (BBM) compared with HDM for relapsed MM, and investigate if BBM could offset the anticipated reduction in remission time observed after second ASCT (ASCT2) relative to first ASCT (ASCT1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of medical records of 43 patients with relapsed MM who received BBM following first\u2010line HDM from November 2011 to October 2018 at Uppsala University Hospital, and compared them with a cohort of 43 patients receiving HDM immediately before and after the BBM era.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The Kaplan\u2013Meier estimated reduction in median time to next treatment was 26% for BBM\u2010 and 39% for HDM\u2010treated patients in ASCT2 versus ASCT1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.198), and 15%\u00a0versus 39% in median progression\u2010free survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.0122). The estimated median overall survival after ASCT2 was 72.2 months versus 51.5 months (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.14). Severe adverse events with BBM were consistent with those from HDM alone, although a trend toward increased risk of febrile neutropenia was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with standard HDM, the BBM\u2010protocol in ASCT2 was associated with a smaller decline in progression\u2010free survival relative to the ASCT1, and a consistent trend toward higher effectiveness across other measures. These findings suggest that BBM may help preserve efficacy in the setting of repeated transplantation and underscore the need for larger prospective studies to confirm these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.70288","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:15:24Z","timestamp":1776179724000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adding Bortezomib and Bendamustine to High\u2010Dose Melphalan in Autologous Haematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma\u2014A Single Centre Retrospective Study"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3829-285X","authenticated-orcid":false,"given":"Thomas","family":"Silfverberg","sequence":"first","affiliation":[{"name":"Department of Medical Sciences Uppsala University  Uppsala Sweden"},{"name":"Center for Clinical Research Dalarna Uppsala University  Falun Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honar","family":"Cherif","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Uppsala University  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Smitt","sequence":"additional","affiliation":[{"name":"Department of Medicine Section of Haematology G\u00e4vle Hospital  G\u00e4vle Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Carlson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Uppsala University  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0805626"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(03)01077\u20105"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.07.030"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30756\u20107"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010020\u201000359\u20102"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)70245\u20101"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(16)30049\u20107"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010019\u20100205\u20109"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_11_17_1","first-page":"1136","article-title":"The Proteasome Inhibitor PS\u2010341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents","volume":"9","author":"Ma M. H.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102009\u201006\u2010229658"},{"issue":"1","key":"e_1_2_11_19_1","first-page":"398","article-title":"Bortezomib and High\u2010Dose Melphalan vs. High\u2010Dose Melphalan as Conditioning Regimen Before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014\u201302)","volume":"130","author":"Roussel M.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.125"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201007\u20101061"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0074-4"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0388"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2013.01.020"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.02.013"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.94"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2546"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010019\u20100587\u20100"},{"key":"e_1_2_11_29_1","unstructured":"\u201cPopulation Statistics\u2014Quarter 4 2022 \u201dStatistics Sweden 2023 https:\/\/www.scb.se\/en\/finding\u2010statistics\/statistics\u2010by\u2010subject\u2010area\/population\/population\u2010composition\/population\u2010statistics\/pong\/tables\u2010and\u2010graphs\/population\u2010statistics\u2014month\u2010quarter\u2010half\u2010year\/population\u2010statistics\u2014quarter\u20104\u20102022\/."},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)70442\u20105"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30206\u20106"},{"key":"e_1_2_11_32_1","unstructured":"\u201cCommon Terminology Criteria for Adverse Events (CTCAE) v5.0 \u201dUS Department of Health and Human Services National Cancer Institute published November 27 2017 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5X7.pdf."},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.10.044"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70288","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.70288","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T17:15:59Z","timestamp":1777223759000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/jha2.70288"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70288","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70288"}}